Eli Lilly to Sign $2bn AI Drug Deal in Hong Kong

By The BriefBrief

Eli Lilly partners with a Hong Kong biotech firm for AI drug development, marking a significant investment in China's pharmaceutical market.

WHO: Eli Lilly

WHAT: sign a $2bn deal for AI drug development

WHEN: Mar 29, 2026 at 7:00 AM ET

WHERE: Hong Kong

WHY: to search for new medicines in China

Sources (2): Financial Times, South China Morning Post

How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.

Know more. Read less.

The BriefBrief — updated continuously, every category, every day.

Cost Breakdown of Enjoying Smokies Games in Knoxville

Smokies Apr 4, 2026 at 12:00 AM ET

Tokyo Cherry Blossom Trees Collapse Raises Safety Concerns

Safety Apr 4, 2026 at 12:00 AM ET

Tighter Water Restrictions Imminent in Tampa Bay

Drought Apr 4, 2026 at 12:00 AM ET

First Previous 25518 25519 25520

Page 25520 of 25520